Hengrui Pharma secures 64 research presentations at ESMO 2026, showcasing significant progress in its oncology pipeline with a focus on HER2- and HER3-targeted therapeutic innovations.
Hengrui Pharma has demonstrated significant R&D momentum with 64 research findings accepted at the ESMO 2026 conference. The inclusion of three Proffered Paper and three Rapid Oral presentations highlights the company's strong clinical positioning in oncology, particularly regarding its HER2- and HER3-targeted therapy pipeline.
Hengrui Pharma had 64 research findings accepted for the conference.
The research spans more than ten areas of oncology and supportive care, with a specific focus on HER2- and HER3-targeted therapies.
Jiangsu Hengrui Pharmaceuticals announced that 64 of its research findings have been accepted for presentation at the ESMO 2026 congress. The portfolio includes six high-profile oral presentations focusing on advancements in HER2- and HER3-targeted therapies across ten oncology and supportive care domains.
The acceptance of 64 research findings demonstrates the company's robust R&D capabilities and provides a platform to showcase clinical progress in targeted oncology treatments to the global medical community.